STOCK TITAN

MiNK Therapeutics Inc - INKT STOCK NEWS

Welcome to our dedicated news page for MiNK Therapeutics (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on MiNK Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MiNK Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MiNK Therapeutics's position in the market.

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its third quarter 2023 financial results on Nov. 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.57%
Tags
-
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) plans to unveil updated clinical and translational data on agenT-797's mechanism of action in solid tumors at the SITC Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
Rhea-AI Summary
MiNK Therapeutics (Nasdaq: INKT) announces CEO participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences
Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) reported significant clinical progress with agenT-797, an allogeneic iNKT therapy, showing persistence and clinical benefit in patients with solid tumor cancers. The company announced a planned launch of a randomized Phase 2 trial in 2L gastric cancer, as well as progress on a novel FAP-CAR-iNKT cell therapy, MiNK-215, that eliminated tumors in NSCLC models. Financial results indicated a cash balance of $10.6 million at the end of the second quarter 2023, with a net loss of $11.9 million for the first six months of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary
MiNK Therapeutics, Inc. provided a corporate update and reported financial results for the first quarter 2023. Their lead program, agenT-797, showed promising results in advanced solid cancers and they have launched expansion studies in NSCLC and gastric cancer. They also announced the development of a novel FAP-CAR-iNKT therapy. MiNK will present new data on their allogeneic FAP-CAR-iNKT program at the ASGCT Annual Meeting. They ended the first quarter with a cash balance of $14.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
Rhea-AI Summary
Agenus Inc. provides a corporate update and reports financial results for Q1 2023. The botensilimab/balstilimab combination shows promising results in colorectal and ovarian cancer patients. The FDA granted Fast Track Designation to the combination for colorectal cancer. Agenus plans to advance its development programs and make botensilimab available to patients as soon as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
MiNK Therapeutics Inc

Nasdaq:INKT

INKT Rankings

INKT Stock Data

34.17M
10.01M
71.34%
2.99%
0.12%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
New York